In Brief: Neuromedical Systems, Inc.
This article was originally published in The Gray Sheet
Neuromedical Systems, Inc.: Gains FDA approval Oct. 24 to promote its Papnet automated Pap smear reader as more effective than manual rescreening of negative slides. The supplemental approval allows NSI to claim that "Papnet testing of routine, presumed negative Pap smears, can be conservatively expected to identify at least 7.1 [times] more false negatives than manual re-examination of the same number of smears," the company says, adding that Papnet is "the only Pap smear testing method available...for which this claim can be made." Data supporting the supplemental approval came from a study of over 16,000 patients submitted to the agency in January...
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.